Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.58 |
| ▸ | CCR5 | P51681 | 8/20 | 0.53 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.52 |
| ▸ | MTR | Q99707 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8199416 | 0.98 | KCNA3 (0.69) | KCNA3CYP2D6SIGMAR1CCR5OPRL1 | |
| Hydrochloric Acid SCHEMBL4218305 | 0.98 | KCNA3 (0.69) | KCNA3CYP2D6SIGMAR1CCR5OPRL1 | |
| SCHEMBL6079135 | 0.92 | KCNA3 (0.64) | KCNA3CYP2D6SIGMAR1CCR5OPRL1 | |
| SCHEMBL6079142 | 0.92 | KCNA3 (0.64) | KCNA3CYP2D6SIGMAR1CCR5OPRL1 | |
| SCHEMBL6079873 | 0.92 | KCNA3 (0.64) | KCNA3CYP2D6SIGMAR1CCR5OPRL1 | |
| Trifluoroacetic Acid SCHEMBL5858602 | 0.87 | KCNA3 (0.59) | KCNA3CYP2D6CCR5OPRL1OPRM1 | |
| SCHEMBL6700772 | 0.85 | KCNA3 (0.53) | KCNA3 | |
| SCHEMBL5857422 | 0.85 | KCNA3 (0.53) | KCNA3 | |
| SCHEMBL6079642 | 0.83 | KCNA3 (0.53) | KCNA3CYP2D6SIGMAR1CCR5 | |
| SCHEMBL6080224 | 0.83 | KCNA3 (0.53) | KCNA3CYP2D6SIGMAR1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110313144-A1 | iRNA Agents Targeting CCR5 Expressing Cells And Uses Thereof | ALNYLAM PHARMACEUTICALS, INC. | 2011-12-22 | — | — | US | disclosed |
| US-8034921-B2 | Chemokine receptors (CCR5); double stranded RNA; gene knockout | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-20090054451-A1 | Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity | EUROSCREEN S.A. (BE) | 2009-02-26 | — | — | US | disclosed |
| US-20090054451-A1 | Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity | EUROSCREEN S.A. (BE) | 2009-02-26 | — | — | US | disclosed |
| WO-2009010478-A2 | USE OF PIPERIDINE DERIVATIVES AS AGONISTS OF CHEMOKINE RECEPTOR ACTIVITY | EUROSCREEN S.A. (BE) | 2009-01-22 | — | — | WO | disclosed |
| US-20080255345-A1 | IRNA Agents Targeting CCR5 Expressing Cells And Uses Thereof | ALNYLAM PHARMACEUTICALS, INC. | 2008-10-16 | — | — | US | disclosed |
| US-6989393-B2 | Ccr5 modulators benzimidazoles or benzotriazoles | ASTRAZENECA AB (SE) | 2006-01-24 | — | — | US | disclosed |
| US-20040006081-A1 | Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2004-01-08 | — | — | US | disclosed |
| CN-1441781-A | Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity | ASTRAZENECA AG (SE) | 2003-09-10 | — | — | CN | disclosed |
| US-20030166590-A1 | Microsomal triglyceride transfer protein | WETTERAU JOHN R (US) | 2003-09-04 | — | — | US | disclosed |
| US-6492365-B1 | Microsomal triglyceride transfer protein | BRISTOL-MYERS SQUIBB COMPANY | 2002-12-10 | — | — | US | disclosed |
| WO-2001087839-A1 | PHARMACEUTICALLY ACTIVE PIPERIDINE DERIVATIVES, IN PARTICULAR AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2001-11-22 | — | — | WO | disclosed |
| WO-2001066525-A1 | NEW CCR5 MODULATORS: BENZIMIDAZOLES OR BENZOTRIAZOLES | ASTRAZENECA AB (SE) | 2001-09-13 | — | — | WO | disclosed |
| US-6066650-A | USEFUL FOR LOWERING SERUM LIPIDS AND TREATING ATHEROSCLEROSIS AND RELATED DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-05-23 | — | — | US | disclosed |
| US-6034098-A | ATHEROSCLEROSIS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-03-07 | — | — | US | disclosed |
| US-5883099-A | TREATMENT OF ATHERSCLEROSIS, PANCREATITIS OBESITY OR HYPERGLYCEMIA | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-03-16 | — | — | US | disclosed |
| US-5789197-A | GENETIC ENGINEERING | E. R. SQUIBB & SONS, INC. (US) | 1998-08-04 | — | — | US | disclosed |
| US-5739135-A | PREVENTING OR TREATING ATHEROSCLEROSIS, PANCREATITIS SECONDARY TO HYPERTRIGLYCERIDEMIA, HYPERGLYCEMIA, OBESITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-04-14 | — | — | US | disclosed |
| US-5595872-A | DNA SEQUENCES, CELLS AND EXPRESSION VECTORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-01-21 | — | — | US | disclosed |
| EP-0643057-A1 | Inhibitors of microsomal triglyceride transfer protein | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255345-A1 | IRNA Agents Targeting CCR5 Expressing Cells And Uses Thereof | CCR5, CXCR3, CCR2 | KCNA3 4632/4885CYP2D6 4844/4885SIGMAR1 2032/4885 |
| US-20030166590-A1 | Microsomal triglyceride transfer protein | MTTP, CETP, HDLBP | KCNA3 4577/4885CYP2D6 2230/4885SIGMAR1 2862/4885 |
| US-20090054451-A1 | Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity | ACKR3, CCR5, CCR7 | KCNA3 1167/4885CYP2D6 2803/4885SIGMAR1 129/4885 |
| US-20040006081-A1 | Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity | CCR5, CCR2, CCR1 | KCNA3 2564/4885CYP2D6 1355/4885SIGMAR1 450/4885 |
| US-20110313144-A1 | iRNA Agents Targeting CCR5 Expressing Cells And Uses Thereof | CCR5, CXCR3, CCR2 | KCNA3 4632/4885CYP2D6 4844/4885SIGMAR1 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.